Ebos Group Limited

EBO.AX

Medical - Distribution · Healthcare

Price

A$18.96

-0.62 (-3.17%)

Market Cap

A$3.89B

Exchange

Australian Securities Exchange

Winston Score

Winston is serious

Mixed quality — meaningful strengths and weaknesses.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Good

Cash Flow

Strong

Stability

Good

Valuation

Strong

Dividends

Good

Track this stock — start free trial

Share count rising — dilution

+16.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 176.9M (2022) → 206.5M (2026)

Winston Score History

The full picture

EBOS Group is a distributor of healthcare products across Australia and New Zealand. It delivers medicines, medical devices, and other health supplies to pharmacies, hospitals, and aged care facilities. The company also owns the Chemist Warehouse distribution contract, which is one of the largest pharmacy supply agreements in the region.

EBOS makes money by buying products from manufacturers and selling them to healthcare providers, earning a small margin on each transaction — a classic distribution model. It operates primarily in Australia and New Zealand, with some animal care operations adding to its revenue mix. Its scale and long-term contracts give it a competitive edge, but thin margins mean any loss of a major contract, like Chemist Warehouse, or pricing pressure from suppliers could have an outsized impact on profits.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+3.9% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-9.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

A$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

4.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

A$378M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Ebos Group Limited is growing revenue at 4% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

7.1%

Thin — 7.1% gross margin

Profit after running costs

Operating Margin

2.9%

Thin — 2.9% operating margin

Return on the money invested

ROCE

9.2%

Below par — 9.2% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+6.6%

Slow sales growth (+6.6% YoY)

Profit growth

EPS YoY

+32.1%

Earnings growing fast (+32.1% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

157%

Turns 157% of profit into real cash

Spare cash per sale

FCF Margin

1.6%

Thin free cash flow (1.6%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.46

Conservative — low debt load (0.46)

Covers its interest

Interest Cover

3.03x

Tight — interest eats into profit (3.0x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

17.7x

Fair value — P/E 17.7

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year

P/E vs Forward

+6.8

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (17.7 → 11.0)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

5.52%

Healthy income — 5.52% yield

Generous yield. Worth checking whether the payout is sustainable.

Dividend record

Dividend Growth

+2.1%

Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial